Eir Ventures, a Stockholm, and Copenhagen, Denmark-based life science venture firm, held the first close of its new fund of EUR76m.
Bagsværd, Denmark-based global healthcare company Novo Nordisk A/S (New York Stock Exchange: NVO) is to acquire Corvidia Therapeutics Inc., a Waltham, Massachusetts-based clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases.
Likvido, a Copenhagen, Denmark-based fintech startup, raised €2.5m in seed funding.
Servier, a Paris, France-based independent international pharmaceutical company, completed the acquisition of Symphogen A/S.
Good Monday, a Copenhagen, Denmark-based workspace management company, raised $4M in funding.
Podimo, a Copenhagen, Denmark-based podcasting provider, secured €15m in funding.
CathVision, a Copenhagen, Denmark-based medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, completed an investment round of a total €13M.
Templafy, a Copenhagen, Denmark based provider of enterprise document creation and automation, closed a $25m Series C funding round.
Nordic API Gateway, a Copenhagen, Denmark-based fintech startup delivering banks’ account to account (A2A) payments, raised €4.6m in funding.
Lunar, a Nordic challenger bank, raised €20m in an additional Series B funding round now totalling €46m.
Yokogawa Electric Corporation (TOKYO: 6841) completed the acquisition of Grazper Technologies ApS, a Copenhagen, Denmark-based provider of Ai for image analytics.
The Org, a New York City and Copenhagen, Denmark-based platform for users to explore any company’s organizational chart, raised $8.5M in Series A funding.
Dixa, a Copenhagen, Denmark-based SaaS startup offering a customer service platform for more personal customer service, raised $36M in Series B funding.
Monsido, a San Diego, CA-based provider of web governance solutions that enhance user experience, secured $16.9m in funding.
Biograil ApS, a Danish biotechnology company developing a unique oral device for delivery of biologics that would otherwise be injected, closed a €3m seed funding.